What are your biggest takeaways from the MASH-TAG 2025 conference?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

In what kind of patient scenario would you consider testing for inherited disorders of lipid metabolism in the evaluation of a patient with MASLD?

2 Answers

In lean MASLD with visceral adiposity (and/or high-risk metabolic/genetic features) in an already physically active patient, when do you recommend additional weight loss versus focusing on diet quality and central adiposity reduction, and how do you monitor to avoid clinically meaningful loss of lean mass?

1 Answers

For patients with mixed metabolic- and alcohol-associated liver disease (or ongoing moderate alcohol use) who otherwise meet presumed F2–F3 criteria by NITs, how do you operationalize initiation and monitoring of a GLP-1 receptor agonist, particularly how you interpret NIT trends when alcohol intake (and inflammation) may be changing during treatment?

1 Answers

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service